I agree that this site is using cookies. You can find further informations here.
X
Kuehbacher, T
19  results:
Search for persons X
?
1

P789 Impact of risk factors for Janus kinase inhibitor use ..:

Siegmund, B ; Kuehbacher, T ; Armuzzi, A...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1471-i1473 , 2024
Link: https://doi.org/10.1093/..
 
?
2

P705 Assessment of age on the efficacy and safety among pat..:

Lichtenstein, G R ; Allegretti, J R ; Loftus Jr, E V...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1330-i1332 , 2024
Link: https://doi.org/10.1093/..
 
?
3

OP02 Ustekinumab versus adalimumab for induction and mainte..:

Irving, P M ; Sands, B E ; Hoops, T...
Journal of Crohn's and Colitis.  15 (2021)  Supplement_1 - p. S001-S002 , 2021
Link: https://doi.org/10.1093/..
 
?
4

P544 Combination therapy of vedolizumab and a TNF antagonis..:

Kuehbacher, T. ; Abu Hashem, R. ; Langel, N...
Journal of Crohn's and Colitis.  11 (2017)  suppl_1 - p. S357-S357 , 2017
Link: https://doi.org/10.1093/..
 
?
5

P588 Ustekinumab for the treatment of Crohn's disease patie..:

Kuehbacher, T. ; Abu Hashem, R. ; Langel, N...
Journal of Crohn's and Colitis.  11 (2017)  suppl_1 - p. S380-S380 , 2017
Link: https://doi.org/10.1093/..
 
?
6

OP023 Maintenance of clinical effect in patients with moder..:

Vermeire, S. ; Schreiber, S. ; Petryka, R....
Journal of Crohn's and Colitis.  11 (2017)  suppl_1 - p. S13-S14 , 2017
Link: https://doi.org/10.1093/..
 
?
7

DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, ..:

D'Haens, G. ; Schreiber, S. ; Petryka, R....
Journal of Crohn's and Colitis.  11 (2017)  suppl_1 - p. S70-S71 , 2017
Link: https://doi.org/10.1093/..
 
?
8

Endoscopic ultrasound of the colon for the differentiation ..:

Ellrichmann, M. ; Wietzke‐Braun, P. ; Dhar, S....
Alimentary Pharmacology & Therapeutics.  39 (2014)  8 - p. 823-833 , 2014
Link: https://doi.org/10.1111/..
 
?
9

Influence of CYP3A4, CYP3A5, and ABCB1 Genotype and Express..:

Ufer, M ; Dilger, K ; Leschhorn, L...
Clinical Pharmacology & Therapeutics.  84 (2008)  1 - p. 43-46 , 2008
Link: https://doi.org/10.1038/..
 
?
10

Signaltrassduction-factor NFκB p65 is activated in patients..:

KUEHBACHER, T ; MIMURA, T ; HELWIG, U...
Gastroenterology.  120 (2001)  5 - p. A516-A516 , 2001
Link: https://doi.org/10.1016/..
 
?
11

Improvement of arthritis/arthralgia after treatment with in..:

ANDUS, T ; HERFARTH, H ; OBERMEIER, F...
Gastroenterology.  120 (2001)  5 - p. A621-A621 , 2001
Link: https://doi.org/10.1016/..
 
?
12

Prediction of response to treatment with infliximab (Remica..:

ANDUS, T ; HERFARTH, H ; OBERMEIER, F...
Gastroenterology.  120 (2001)  5 - p. A621-A621 , 2001
Link: https://doi.org/10.1016/..
 
?
13

Four week treatment of metronidazole and ciprofloxacin mark..:

MIMURA, T ; RIZZELLO, F ; GIONCHETTI, P...
Gastroenterology.  120 (2001)  5 - p. A453-A453 , 2001
Link: https://doi.org/10.1016/..
 
?
14

Clinical efficacy of treatment with infliximab in a german ..:

Schreiber, S. ; Kuehbacher, T. ; Mascheretti, S....
Gastroenterology.  118 (2000)  4 - p. A568 , 2000
Link: https://doi.org/10.1016/..
 
?
15

Efficacy of Filgotinib, a Selective jak1 Inhibitor, is Inde..:

D'Haens, Geert R. ; Schreiber, Stefan ; Petryka, Robert...
Gastroenterology.  152 (2017)  5 - p. S597 , 2017
Link: https://doi.org/10.1016/..
 
1-15